Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis
Hudson J, Cruickshank M, Quinton R, Aucott L, Aceves-Martins M, Gillies K, Bhasin S, Snyder P, Ellenberg S, Grossmann M, Travison T, Gianatti E, van der Schouw Y, Emmelot-Vonk M, Giltay E, Hackett G, Ramachandran S, Svartberg J, Hildreth K, Antonic K, Brock G, Tenover J, Tan H, Kong C, Tan W, Marks L, Ross R, Schwartz R, Manson P, Roberts S, Andersen M, Magnussen L, Hernández R, Oliver N, Wu F, Dhillo W, Bhattacharya S, Brazzelli M, Jayasena C. Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. The Lancet Healthy Longevity 2022, 3: e381-e393. PMID: 35711614, PMCID: PMC9184259, DOI: 10.1016/s2666-7568(22)00096-4.Peer-Reviewed Original ResearchConceptsRisk of biasMeta-analysisStudy designSystematic reviewInclusion criteriaCochrane Database of Systematic ReviewsCochrane risk of bias toolDatabase of Systematic ReviewsRisk of bias toolMEDLINE In-Process & Other Non-Indexed CitationsIn-Process & Other Non-Indexed CitationsTwo-stage meta-analysisCharacteristics of interventionsOther Non-Indexed CitationsMeta-analysis of randomised controlled trialsOne-stage meta-analysisFull-text screeningRandomised controlled trialsNon-Indexed CitationsCardiovascular eventsAggregate data meta-analysisCoronary heart diseaseData meta-analysisPeer-reviewed publicationsCochrane Controlled Trials Register